Skip to main content

Table 1 Demographic details of the study population

From: Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation

  Type of injections
Ranibizumab (n = 69) Bevacizumab (n = 66) Biosimilar ranibizumab (n = 67)
Age (years)    
 Mean 66.36 ± 9.53 62 ± 13.95 58.49 ± 13.026
 Range 50–87 27–88 26–84
Sex n (%)    
 Male 43 (62.3) 41 (62.1) 41(61.2)
 Female 26 (37.7) 25 (37.9) 26 (38.8)
Eye n (%)    
 Right eye 35 (50.7) 33 (50.0) 32 (47.8)
 Left eye 34 (49.3) 33 (50.0) 35 (52.2)
Previous treatment n (%)    
 Treatment naïve 62 (89.9) 57 (86.4) 62 (92.5)
 Previous BEV 7 (10.1) 3 (4.5) 1 (1.5)
 Previous RBZ 0 5 (7.7) 0
 Previous IVTA 0 1 (1.5) 1 (1.5)
 Previous laser 0 0 3 (4.5)
Comorbidities n (%)    
 Nil 14 (25.5) 19 (34.5) 20 (29.9)
 Hypertension 49 (71.0) 35 (53.0) 30 (44.7)
 Diabetics 33 (47.8) 37 (56.1) 31 (46.3)
 Ischemic heart disease 4 (5.8) 0 1 (1.5)
Diagnosis n (%)    
 ME 29 (42.0) 31 (47.0) 27 (40.1)
 nAMD 40 (58.0) 35 (53.0) 40 (59.7)
Follow-up duration (months)    
 Mean ± SD 14.64 ± 12.46 11.03 ± 5.24 7.79 ± 5.40
 Range 4–78 6–22 3–21
  1. IVTA intravitreal triamcinolone acetonide, ME macular edema, nAMD neovascular age-related macular degeneration